CG Oncology Balance Sheet
NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
CG Oncology financial position
At the end of fiscal 2025, CG Oncology reported total assets of $791.6 million, up 4.9% from a year earlier against total liabilities of $39.0 million. Shareholders' equity stood at $752.6 million, or 95.1% of assets. The company held $32.5 million in cash and equivalents against $3.0 million of debt, a net cash position of $29.5 million.
The current ratio (current assets divided by current liabilities) was 24.63, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.00.
Summary generated from market data by MetaCap's automated system. Methodology
CG Oncology balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Cash & Equivalents | 32.49M | 257.07M | 8.27M |
| Short-Term Investments | 709.66M | 484.93M | 179.41M |
| Receivables | 688.00K | 0 | — |
| Inventory | 1.56M | 0 | — |
| Total Current Assets | 759.48M | 754.21M | 194.12M |
| Property, Plant & Equipment | 15.60M | 272.00K | 69.00K |
| Goodwill | 10.30M | 0 | — |
| Intangible Assets | 575.00K | 0 | — |
| Total Assets | 791.59M | 754.80M | 199.30M |
| Accounts Payable | 5.71M | 6.52M | 3.24M |
| Total Current Liabilities | 30.84M | 21.37M | 14.25M |
| Long-Term Debt | 3.00M | 0 | — |
| Total Liabilities | 38.99M | 21.42M | 14.51M |
| Shareholders' Equity | 752.60M | 733.38M | -123.10M |
| Retained Earnings | -378.98M | -217.98M | -129.94M |
| Total Debt | 3.00M | 0 | — |
| Net Cash (Debt) | 739.15M | 742.00M | 187.67M |
| Shares Outstanding | 80.69M | 76.15M | 5.22M |
This table shows 3 annual periods of CG Oncology's balance sheet, from FY 2025 back to FY 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CGON's reporting calendar. What is a balance sheet?